279 related articles for article (PubMed ID: 32441783)
1. A rationale for targeting the P2X7 receptor in Coronavirus disease 19.
Di Virgilio F; Tang Y; Sarti AC; Rossato M
Br J Pharmacol; 2020 Nov; 177(21):4990-4994. PubMed ID: 32441783
[TBL] [Abstract][Full Text] [Related]
2. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.
Robb CT; Goepp M; Rossi AG; Yao C
Br J Pharmacol; 2020 Nov; 177(21):4899-4920. PubMed ID: 32700336
[TBL] [Abstract][Full Text] [Related]
4. Targeting zinc metalloenzymes in coronavirus disease 2019.
Doboszewska U; Wlaź P; Nowak G; Młyniec K
Br J Pharmacol; 2020 Nov; 177(21):4887-4898. PubMed ID: 32671829
[TBL] [Abstract][Full Text] [Related]
5. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.
Cleary SJ; Pitchford SC; Amison RT; Carrington R; Robaina Cabrera CL; Magnen M; Looney MR; Gray E; Page CP
Br J Pharmacol; 2020 Nov; 177(21):4851-4865. PubMed ID: 32462701
[TBL] [Abstract][Full Text] [Related]
6. Statins: Could an old friend help in the fight against COVID-19?
Rodrigues-Diez RR; Tejera-Muñoz A; Marquez-Exposito L; Rayego-Mateos S; Santos Sanchez L; Marchant V; Tejedor Santamaria L; Ramos AM; Ortiz A; Egido J; Ruiz-Ortega M
Br J Pharmacol; 2020 Nov; 177(21):4873-4886. PubMed ID: 32562276
[TBL] [Abstract][Full Text] [Related]
7. The potential of cannabidiol in the COVID-19 pandemic.
Esposito G; Pesce M; Seguella L; Sanseverino W; Lu J; Corpetti C; Sarnelli G
Br J Pharmacol; 2020 Nov; 177(21):4967-4970. PubMed ID: 32519753
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H
Citi V; Martelli A; Brancaleone V; Brogi S; Gojon G; Montanaro R; Morales G; Testai L; Calderone V
Br J Pharmacol; 2020 Nov; 177(21):4931-4941. PubMed ID: 32783196
[TBL] [Abstract][Full Text] [Related]
9. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019.
Colarusso C; Terlizzi M; Pinto A; Sorrentino R
Br J Pharmacol; 2020 Nov; 177(21):4866-4872. PubMed ID: 32497257
[TBL] [Abstract][Full Text] [Related]
10. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
[TBL] [Abstract][Full Text] [Related]
11. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
Bertocchi I; Foglietta F; Collotta D; Eva C; Brancaleone V; Thiemermann C; Collino M
Br J Pharmacol; 2020 Nov; 177(21):4921-4930. PubMed ID: 32776354
[TBL] [Abstract][Full Text] [Related]
12. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.
Sriram K; Insel PA
Br J Pharmacol; 2020 Nov; 177(21):4825-4844. PubMed ID: 32333398
[TBL] [Abstract][Full Text] [Related]
13. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19?
Sriram K; Insel PA
Br J Pharmacol; 2020 Nov; 177(21):4971-4974. PubMed ID: 32639031
[TBL] [Abstract][Full Text] [Related]
14. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
15. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
16. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
Alexander SPH; Armstrong JF; Davenport AP; Davies JA; Faccenda E; Harding SD; Levi-Schaffer F; Maguire JJ; Pawson AJ; Southan C; Spedding M
Br J Pharmacol; 2020 Nov; 177(21):4942-4966. PubMed ID: 32358833
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Zhou D; Dai SM; Tong Q
J Antimicrob Chemother; 2020 Jul; 75(7):1667-1670. PubMed ID: 32196083
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
Smetana K; Rosel D; BrÁbek J
In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
20. Current pharmacological treatments for COVID-19: What's next?
Scavone C; Brusco S; Bertini M; Sportiello L; Rafaniello C; Zoccoli A; Berrino L; Racagni G; Rossi F; Capuano A
Br J Pharmacol; 2020 Nov; 177(21):4813-4824. PubMed ID: 32329520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
